Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2011) 27 P11

BSPED2011 Poster Presentations (1) (84 abstracts)

Audit of use of transdermal oestradiol for pubertal induction in girls

Debbie Matthews


Great North Children’s Hospital, Newcastle upon Tyne, UK.


Girls with ovarian failure or delayed puberty may be treated with incremental doses of oestrogen to induce puberty. Transdermal natural oestradiol is more physiological than oral synthetic ethinyl oestradiol but it is unclear how effective it is for inducing puberty and whether it confers any benefit.

The aims of the audit were to review whether transdermal oestradiol was effective in inducing puberty, the optimal dosing regimen, effects on breast development & uterine growth, adolescent growth spurt, and the usefulness of serum levels of oestradiol in monitoring therapy.

Twenty prepubertal girls attending a paediatric endocrine unit were studied using a retrospective clinical notes review. Ten girls were treated with transdermal oestradiol (Evorel) and ten girls were treated with oral ethinyloestradiol.

Transdermal group: The median age at start of treatment was 12.7 years, with starting dose 4–12.5 μg. The median height gain was 10.6 cm over 2 years. Three girls had poor breast development. Breakthrough bleeding occurred in five girls at variable doses of oestradiol (6.25–25 μg). Pelvic ultrasound scan in four showed a mature uterus but small in two. The medication was well tolerated. Serum oestradiol levels were variable (<60–278 pmol/l).

Oral ethinyl oestradiol group: The median age at start of treatment was 12.6 years with starting dose 1–4 μg. The median height gain was 14 cm over 2 years. One girl had poor breast development and had compliance issues. Breakthrough bleeding occurred in seven girls at variable doses (6–10 μg). Pelvic ultrasound scan in four girls showed a mature uterus in three, small uterus in one.

Conclusion: Puberty can be induced in girls using transdermal oestradiol. However, further work is needed to establish the optimal dosing regimen. It is unclear whether there are any advantages to the transdermal approach.

Volume 27

39th Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.